<DOC>
	<DOCNO>NCT00803712</DOCNO>
	<brief_summary>Randomized Trial Evaluate Efficacy Safety Cinacalcet Treatment Combination Low Dose Vitamin D Treatment Subjects Secondary Hyperparathyroidism ( SHPT ) Recently Initiating Hemodialysis</brief_summary>
	<brief_title>20070360 Incident Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Adults great equal 18 year age hemodialysis &gt; 3 less equal 12 month prior enrollment study Mean 2 PTH determination screen period ( draw least 2 day apart ) &gt; 300 pg/mL ( 31.8 pmol/L ) ; biPTH &gt; 160 pg/mL ( 17.0 pmol/L ) Mean 2 correct serum calcium determination draw day PTH determination great equal 8.4 mg/dL ( 2.1 mmol/L ) Subject able complete study , best his/her knowledge Before studyspecific procedure , appropriate write informed consent must obtain Mean 2 PTH determination screen period ( draw least 2 day apart ) &gt; 800 pg/mL ( 84.9 pmol/L ) ; biPTH &gt; 430 pg/mL ( 45.6 pmol/L ) AND receive vitamin D enter screen Parathyroidectomy ( partial full ) less equal 6 month enter screen Anticipated parathyroidectomy ( partial full ) within 6 month randomization Have schedule date kidney transplant surgery Received cinacalcet since initiate hemodialysis Have receive vitamin D therapy le 30 day enter screening require change prescribe vitamin D brand dose within 30 day enter screening . If subject receive vitamin D therapy , must remain free vitamin D therapy 30 day enter screen Subject pregnant ( eg , positive HCG test ) breastfeeding Refusal use highly effective contraceptive measure ( determine investigator ) throughout study ( screen post enrollment ) Current gastrointestinal disorder may associate impaired absorption orally administer medication inability swallow tablet Known sensitivity , intolerance , adverse response cinacalcet would prevent onstudy treatment compliance Have unstable medical condition within 30 day screen , otherwise unstable judgment investigator Subject currently enrol , few 30 day prior enter screen pass since subject receive investigational agent ( ) ( device drug ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>